Immune Pharmaceuticals Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Immune Pharmaceuticals Inc. – Product Pipeline Review, 2016’, provides an overview of the Immune Pharmaceuticals Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Immune Pharmaceuticals Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Immune Pharmaceuticals Inc.

The report provides overview of Immune Pharmaceuticals Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Immune Pharmaceuticals Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Immune Pharmaceuticals Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Immune Pharmaceuticals Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Immune Pharmaceuticals Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Immune Pharmaceuticals Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Immune Pharmaceuticals Inc. Snapshot 6

Immune Pharmaceuticals Inc. Overview 6

Key Information 6

Key Facts 6

Immune Pharmaceuticals Inc. - Research and Development Overview 7

Key Therapeutic Areas 7

Immune Pharmaceuticals Inc. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Combination Treatment Modalities 12

Pipeline Products - Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

Immune Pharmaceuticals Inc. - Pipeline Products Glance 15

Immune Pharmaceuticals Inc. - Late Stage Pipeline Products 15

Phase III Products/Combination Treatment Modalities 15

Immune Pharmaceuticals Inc. - Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

Immune Pharmaceuticals Inc. - Early Stage Pipeline Products 18

IND/CTA Filed Products/Combination Treatment Modalities 18

Preclinical Products/Combination Treatment Modalities 19

Immune Pharmaceuticals Inc. - Drug Profiles 20

histamine dihydrochloride 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

(amitriptyline + ketamine hydrochloride) 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

bertilimumab 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

crolibulin 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

lidocaine hydrochloride 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

F-573 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

cyclosporine 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Ferritizumab 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Monoclonal Antibodies to Target HLA-DR and CD5 for Leukemia 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Monoclonal Antibody Conjugate for Non-Small Cell Lung Cancer and Pancreatic Cancer 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Monoclonal Antibody Conjugate to Target EGFR for Non-Small Cell Lung Cancer 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Monoclonal Antibody Conjugate to Target HER2 for Metastatic Prostate Cancer 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Monoclonal Antibody Conjugate to Target HER3 for Solid Tumors 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

verubulin 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Immune Pharmaceuticals Inc. - Pipeline Analysis 42

Immune Pharmaceuticals Inc. - Pipeline Products by Target 42

Immune Pharmaceuticals Inc. - Pipeline Products by Route of Administration 44

Immune Pharmaceuticals Inc. - Pipeline Products by Molecule Type 45

Immune Pharmaceuticals Inc. - Pipeline Products by Mechanism of Action 46

Immune Pharmaceuticals Inc. - Recent Pipeline Updates 48

Immune Pharmaceuticals Inc. - Dormant Projects 57

Immune Pharmaceuticals Inc. - Discontinued Pipeline Products 58

Discontinued Pipeline Product Profiles 58

histamine dihydrochloride 58

verubulin 58

Immune Pharmaceuticals Inc. - Locations And Subsidiaries 59

Head Office 59

Other Locations & Subsidiaries 59

Appendix 60

Methodology 60

Coverage 60

Secondary Research 60

Primary Research 60

Expert Panel Validation 60

Contact Us 60

Disclaimer 61

List of Tables

List of Tables

Immune Pharmaceuticals Inc., Key Information 6

Immune Pharmaceuticals Inc., Key Facts 6

Immune Pharmaceuticals Inc. – Pipeline by Indication, 2016 8

Immune Pharmaceuticals Inc. – Pipeline by Stage of Development, 2016 10

Immune Pharmaceuticals Inc. – Monotherapy Products in Pipeline, 2016 11

Immune Pharmaceuticals Inc. – Combination Treatment Modalities in Pipeline, 2016 12

Immune Pharmaceuticals Inc. – Partnered Products in Pipeline, 2016 13

Immune Pharmaceuticals Inc. – Partnered Products/ Combination Treatment Modalities, 2016 14

Immune Pharmaceuticals Inc. – Phase III, 2016 15

Immune Pharmaceuticals Inc. – Phase II, 2016 16

Immune Pharmaceuticals Inc. – Phase I, 2016 17

Immune Pharmaceuticals Inc. – IND/CTA Filed, 2016 18

Immune Pharmaceuticals Inc. – Preclinical, 2016 19

Immune Pharmaceuticals Inc. – Pipeline by Target, 2016 42

Immune Pharmaceuticals Inc. – Pipeline by Route of Administration, 2016 44

Immune Pharmaceuticals Inc. – Pipeline by Molecule Type, 2016 45

Immune Pharmaceuticals Inc. – Pipeline Products by Mechanism of Action, 2016 46

Immune Pharmaceuticals Inc. – Recent Pipeline Updates, 2016 48

Immune Pharmaceuticals Inc. – Dormant Developmental Projects,2016 57

Immune Pharmaceuticals Inc. – Discontinued Pipeline Products, 2016 58

Immune Pharmaceuticals Inc., Other Locations 59

Immune Pharmaceuticals Inc., Subsidiaries 59

List of Figures

List of Figures

Immune Pharmaceuticals Inc. – Pipeline by Top 10 Indication, 2016 8

Immune Pharmaceuticals Inc. – Pipeline by Stage of Development, 2016 10

Immune Pharmaceuticals Inc. – Monotherapy Products in Pipeline, 2016 11

Immune Pharmaceuticals Inc. – Partnered Products in Pipeline, 2016 13

Immune Pharmaceuticals Inc. – Pipeline by Top 10 Target, 2016 42

Immune Pharmaceuticals Inc. – Pipeline by Route of Administration, 2016 44

Immune Pharmaceuticals Inc. – Pipeline by Molecule Type, 2016 45

Immune Pharmaceuticals Inc. – Pipeline Products by Top 10 Mechanism of Action, 2016 46

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports